Evgen Pharma PLC - clinical stage drug development company - Says a total of 56 patients had been recruited and randomised to the STAR trial as of Monday. This phase II/III randomised, placebo-controlled trial is sponsored by the University of Dundee and funded by the UK charity Life Arc. It will investigate whether the company's lead asset, SFX-01, can reduce the severity, or prevent the onset of, acute respiratory distress syndrome in patients with community-acquired pneumonia from any infective agent and who have been or are being tested for suspected Covid-19.
Current stock price: 9.94 pence, down 3.0% on Tuesday
Year-to-date change: down 3.5%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
